A Databank Study of Molecular Circulatory Biomarkers in Non-localized Renal and Testicular Cancer Patients
Overview
Tab Title Description
Study type
ObservationalDescribes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
Study IDs
Site IRB
- Rochester, Minnesota: 11-005855
- Jacksonville, Florida: 11-005855
Sponsor Protocol Number: 11-005855
About this study
The purpose of this study is to collect blood and urine specimens from cancer patients with non-localized kidney cancer receiving therapeutic interventions and patients with a diagnosis of testicular cancer. To clinically annotate a registry in the patients enrolled for the purpose of developing new cancer related molecular biomarkers for prognosis and prediction of clinical outcomes. This will include proteomic, genomic and metabolomic based molecular profiling in blood and urine specimens collected from cancer patients.
Participation eligibility
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.
Inclusion Criteria:
- Subjects with a histological confirmed diagnosis of testicular cancer who are destined to initiate standard of care therapeutic interventions. This includes testicular cancer subjects with evidence of clinically or biochemically progressive disease post surgical or radiation treatments for localized stage disease as deemed by the treating physician. Biochemical evidence of progressive disease is defined as a serially rising serum tumor marker (AFP-Alpha Feto-Protein; B-HCG-beta human chorionic gonadotropin or LDH).
- Subjects with non-localized kidney cancer being followed or treated at Mayo Clinic as part of standard clinical care.
- Age: 18 to 100 years
- Subject must be able to sign an informed consent. Informed consent must be signed at the time of enrollment and/or collection of any specimen and/or clinical data (other than PHI needed to screen and identify patients, which will be promptly discarded in a secure fashion if patient is not enrolled on study).
Exclusion Criteria:
- Subjects either incarcerated or with limited decision making capacity.
- Subjects clinically judged to be at increased risk of bleeding from phlebotomy.
- Subjects with hemoglobin
- Subjects with a previous history of known second non-GU malignancy in the past five years.
Participating Mayo Clinic locations
Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.
| Mayo Clinic Location |
Status |
Contact |
Rochester, Minn.
Mayo Clinic principal investigator Brian Costello, M.D. |
Closed for enrollment |
Contact information:
Cancer Center Clinical Trials Referral Office
(855) 776-0015
|
Jacksonville, Fla.
Mayo Clinic principal investigator Winston Tan, M.D. |
Closed for enrollment |
Contact information:
Cancer Center Clinical Trials Referral Office
(855) 776-0015
|
More information
Publications
Publications are currently not available